{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gilligan M"],"funding":["National Institutes of Health, USA","Canadian Institute for Theoretical Astrophysics","NINDS NIH HHS","Irish Clinical Academic Training (ICAT)","Wellcome Trust"],"pagination":["213-225"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11752097"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["<h4>Objective</h4>We describe neurologic phenotype, clinical associations, and outcomes in autoimmune brainstem encephalitis.<h4>Methods</h4>Medical records of neural-IgG positive autoimmune brainstem encephalitis patients diagnosed at Mayo Clinic (January 1, 2006-December 31, 2022) were reviewed.<h4>Results</h4>Ninety-eight patients (57 male) were included. Median age of symptom onset was 51 years (range, 8 months-85 years). Frequent presenting features were ≥1: diplopia (80%), ataxia (78%), dysarthria (68%), vestibulocochlear symptoms (67%), dysphagia (61%), nausea/vomiting (42%), and facial weakness (32%). Altered mental status (11%) was uncommon. Neural antibodies detected were as follows: KLHL-11 (26 patients), GAD65 (high titer, 12), ANNA-1 (anti-Hu, 8), ANNA-2 (anti-Ri, 8), Ma2 (7),"],"journal":["Annals of clinical and translational neurology"],"pubmed_title":["Autoimmune brainstem encephalitis: Clinical associations, outcomes, and proposed diagnostic criteria."],"pmcid":["PMC11752097"],"funding_grant_id":["R01 NS113828","203930/B/16/Z","RO1NS126227","R01 NS126227","Grant Number203930/B/16/Z","R01NS113828"],"pubmed_authors":["Valencia Sanchez C","Dubey D","Banks S","Mills JR","Orozco E","Gilligan M","Thakolwiboon S","Tillema JM","McKeon A","Zekeridou A","Pittock SJ","Flanagan EP","Lopez-Chiriboga S"],"additional_accession":[]},"is_claimable":false,"name":"Autoimmune brainstem encephalitis: Clinical associations, outcomes, and proposed diagnostic criteria.","description":"<h4>Objective</h4>We describe neurologic phenotype, clinical associations, and outcomes in autoimmune brainstem encephalitis.<h4>Methods</h4>Medical records of neural-IgG positive autoimmune brainstem encephalitis patients diagnosed at Mayo Clinic (January 1, 2006-December 31, 2022) were reviewed.<h4>Results</h4>Ninety-eight patients (57 male) were included. Median age of symptom onset was 51 years (range, 8 months-85 years). Frequent presenting features were ≥1: diplopia (80%), ataxia (78%), dysarthria (68%), vestibulocochlear symptoms (67%), dysphagia (61%), nausea/vomiting (42%), and facial weakness (32%). Altered mental status (11%) was uncommon. Neural antibodies detected were as follows: KLHL-11 (26 patients), GAD65 (high titer, 12), ANNA-1 (anti-Hu, 8), ANNA-2 (anti-Ri, 8), Ma2 (7),","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2025-04-21T16:49:01.329Z","creation":"2025-04-21T16:49:01.329Z"},"accession":"S-EPMC11752097","cross_references":{"pubmed":["39708293"],"doi":["10.1002/acn3.52273"]}}